FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US.
This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Benefits of the manufacturing expansion
“This investment is an important step to further accelerate the growth of our biopharmaceutical CDMO business,” stated Teiichi Goto, President and Chief Executive Officer, Representative Director, FUJIFILM Corporation.
“Significant” large-scale production capacity will consequently be added to FUJIFILM Diosynth Biotechnologies’ global network.
The expansion means identical large-scale production facilities can be built in US and Europe to support integration drug manufacturing production “regardless of location”, FUJIFILM explained.
The new investment in the Holly Springs facility will “add 8 x 20,000 L mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment”.
This new facility allows for flexibility to expand with additional bioreactors to accommodate new projects, according to FUJIFILM.
Based on these aspects, when the facility is complete, the site will be one of the largest cell culture biopharmaceutical CDMO facilities in North America, FUJIFILM noted.
“We are pleased to continue investing to grow our cell culture manufacturing capabilities in North Carolina in anticipation of the growing outsourcing needs of biopharma companies,” commented Toshihisa Iida, Corporate Vice President of FUJIFILM Corporation and Chairman of FUJIFILM Diosynth Biotechnologies.
Sustainability
To support the delivery of net-zero operations at the facility, FUJIFILM stated that all energy needs for operations is anticipated to be “100 percent offset through the use of renewable landfill gas, onsite solar and the 125,000 MWh of annual sustainable solar energy from a virtual power purchase agreement”.
Furthermore, the company shared that an additional 680 jobs will be created by 2031 due to the expansion.
Source: europeanpharmaceuticalreview.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
